Evidence map›Paper›PMID 24148235›Full record

ReviewCurrent opinion in immunology2013

Natural killer T (NKT) cells in autoimmune hepatitis.

Jochen Mattner

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. The role of natural killer T cells in liver transplantation.Frontiers in cell and developmental biology · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. NKT Cells Contribute to the Control of Microbial Infections.Frontiers in cellular and infection microbiology · 2021
    Review
  11. Article
  12. T Cells in Fibrosis and Fibrotic Diseases.Frontiers in immunology · 2020
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jochen MattnerMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander Universität Erlangen-Nürnberg, D-91054 Erlangen, Germany; Division of Cellular and Molecular Immunology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA. Electronic address: Jochen.Mattner@uk-erlangen.de.

Funding

ROLE OF ANGPTL4, AN ANGIOGENIC MEDIATOR, IN ARTHRITISP30AR047363 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI WAGNER, MICHAEL · 2001 to 2015
$9.2M
Primary biliary cirrhosis: molecular genetics and microbial pathogenesisR01DK084054 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI MATTNER, JOCHEN · 2009 to 2013
$1.5M
NIAMS NIH HHS P30 AR047363NIDDK NIH HHS R01 DK084054NIDDK NIH HHS R01DK084054
6 · The paper itself

Abstract

Natural killer T (NKT) cells represent an innate-like lymphocyte population endowed with unique antigen recognition and tissue distribution features. Their abundance in the microvascular compartments of the liver allows NKT cells to immediately respond to lipid antigens and soluble factors circulating through the portal vein system by releasing tremendous amounts of different cytokines and chemokines. Subsequently, dependent on the nature of the lipid antigen encountered as well as the accessory signal(s) provided, NKT cells not only contribute to the maintenance of immune tolerance, but also direct adverse immune reactions locally and systemically. Focusing on their potent immunomodulatory features and their interactions with various innate and adaptive immune cells, the role of NKT cells in perpetuating the loss of liver-specific immune tolerance will be discussed.

Indexed as

AnimalsFibrosisHepatitis, AutoimmuneHumansImmune ToleranceImmunity, InnateLymphocyte ActivationNatural Killer T-Cells

Identifiers

PMID24148235
PMCPMC4013545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.